Live Markets »News & Advice»Latest Stories»Latest Stories Details
Latest Stories Details

Divis Labs tanks 20% after USFDA issues import alert on Vizag unit

SI Reporter/Mumbai 21 Mar 17 | 09:27 AM
 Divis Laboratories Ltd

BSE   23 Feb 18 | 12:00 AM

1049.55  31.3 (3.07%)

NSE   23 Feb 18 | 12:00 AM

1050.10  30.85 (3.03%)

Shares of Divis Laboratories tanked 20% to Rs 635, also its 52-week low on BSE in early morning trade, after the company said US drug regulator issued an import alert on the company’s Visakhapatnam unit-II.

“The United States Food and Drug Administration (USFDA) have issued an Import Alert 66-40 on 20th March 2017 on the products manufactured at the company's Unit-II at Visakhapatnam, Andhra Pradesh," Divis Laboratories said in a statement.

Related Stories

    No Related Stories Found
Widgets Magazine

“The agency has exempted the 10 active pharmaceutical ingredients (APIs) namely Levetiracetam, Gabapentin, Lamotrigine , Capecitabine, Naproxen Sodium, Raltegravir potassium,  Atovaquone, Chloropurine , BOC core succinate and 2,4-wing active ester from the import alert," it added.

Divis Labs said the company, along with third party consultants, is currently working to address the concerns of the US-FDA and is making all efforts to fully meet the compliance requirements.

At 09:35 am; the stock was down 18% at Rs 646 on BSE as compared to 0.15% rise in the S&P BSE Sensex. The trading volumes on the counter jumped more than five-fold with a combined 6.78 million shares changed hands on the BSE and NSE so far.

Widgets Magazine


Company Price Gain (%)
Tata Steel677.806.26
Sun Pharma.Inds.570.205.17
Yes Bank323.602.28
Dr Reddy's Labs2,169.252.26
Bharti Airtel425.452.26


Will Arun Jaitey recast tax slabs for individuals in Budget 2018?

Online Portfolio

You can create Online Portfolio here using the below button.

Widgets Magazine